25 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA
University of Strathclyde
Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
Astex Pharmaceuticals
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Shanghaitech University
Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Astex Pharmaceuticals
Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Chinese Academy of Sciences
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Chinese Academy of Sciences
Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.
Chinese Academy of Sciences
Amides of 4-hydroxy-8-methanesulfonylamino-quinoline-2-carboxylic acid as zinc-dependent inhibitors of Lp-PLA2.
Activx Biosciences
Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.
The Scripps Research Institute
Amides of xanthurenic acid as zinc-dependent inhibitors of Lp-PLA(2).
Activx Biosciences
Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter.
Central China Normal University
Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime.
National Research Laboratory of Lipid Metabolism and Atherosclerosis
(E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.
National Research Laboratory of Lipid Metabolism and Atherosclerosis
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Glaxosmithkline
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Glaxosmithkline
Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones.
Glaxosmithkline
1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).
Glaxosmithkline
The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2.
Glaxosmithkline
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.
Smithkline Beecham Pharmaceuticals
2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.
Smithkline Beecham Pharmaceuticals
Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.
Abide Therapeutics
Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
University of Reunion
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Shanghaitech University
